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Epigenetic modiﬁcations like DNA methylation and histone acetylation play an important role in a wide range of brain disorders.
Histone deacetylases (HDACs) regulate the homeostasis of histone acetylation. Histone deacetylase inhibitors, which initially
were used as anticancer drugs, are recently suggested to act as neuroprotectors by enhancing synaptic plasticity and learning and
memory in a wide range of neurodegenerative and psychiatric disorders, such as Alzheimer’s disease (AD) and Parkinson’s disease
(PD). To reveal the physiological roles of HDACs may provide us with a new perspective to understand the mechanism of AD and
to develop selective HDAC inhibitors. This paper focuses on the recent research progresses of HDAC proteins and their inhibitors
on the roles of the treatment for AD.
1.Introduction
Alzheimer’s disease (AD), including familiar AD and spo-
radic AD, is a progressive neurodegenerative disease and the
most common form of dementia. This late-onset disorder
is characterized by memory loss and cognitive impairment.
The pathological features are neuroﬁbrillary tangles (NFTs),
insoluble β-amyloid (Aβ) plaques, and neuron loss [1].
According to the most convincing hypothesis at present, the
“amyloid cascade hypothesis,” it is believed that the accumu-
lated Aβ peptide leads to a complex cascade of neuronal
apoptosis and results in the pathogenesis of AD [2, 3]. In-
creasing evidence supports the notion that some genetic
changes in familiar AD, such as amyloid β precursor protein
(APP), presenile 1, 2 (PS1&2), and apolipoprotein E, are
linked to the overproduction of Aβ [4]. Although we have
known a lot about both familiar AD and sporadic AD, it is
still a long way to fully understand the pathogenesis of the
diseases, especially sporadic AD. Epigenetics is a branch of
genetics. Epigenetics studies the gene expression when the
nucleotide sequences of a gene do not change, but rather
other modiﬁcation factors including histone acetylation and
DNA methylation [5]. The epigenetic regulation oﬀers a
new way to understand AD, especially sporadic AD. DNA
methylation has been previously proved to play a role in AD,
andrecentlyseveralstudiessuggestedthathistoneacetylation
is involved in the etiology of AD [6, 7]. Histone acetylation
and deacetylation are catalytic by histone acetyltransferases
(HATs) and histone deacetylases (HDACs), respectively. The
level of histone acetylation plays an important role in reg-
ulating the chromatin condensation and gene transcription
[8]. HDACs regulate the level of histone acetylation and
further aﬀect some downstream gene expression. Abnormal
acetylation of histone is involved in the pathology of AD.
HDAC proteins may be therapeutical targets to treatment
for AD. HDAC inhibitors have been reported to improve the
memory and cognition in the mouse model of AD. HDAC
inhibitors may be alternative drugs to potentially protect the
impairment of cognition in AD patients. However, HDAC
proteins serve a very distinct function in the brain. There-
fore, the use of pan-HDAC inhibitors (nonselective HDAC
inhibitors) in the treatment of neuropsychiatric disorders
should be careful. To identify which numbers of HDAC
family are involved in memory and learning is helpful in
discovering the pathological mechanism of AD and in de-
veloping selective HDAC inhibitors.2 Oxidative Medicine and Cellular Longevity
2. HistoneDeacetylaseandHistone
DeacetylaseInhibition
2.1. Histone Deacetylase. HDAC proteins belong to an an-
cientproteinfamilyinmanyspecies.Infact,contrarytowhat
is suggested by their names, certain HDACs mainly interact
with nonhistone protein. In mammals, there are eighteen
HDACenzymes(Table 1),whicharedividedintofourclasses
based on their homology to yeast: class I, class II, and class
IV. Among these classes, class I, class II, and class IV are zinc-
dependent enzymes, whereas class III is dependent on nico-
tinamide adenine dinucleotide (NAD+)[ 9, 10].
Class I of HDACs, which consists of HDAC 1, 2, 3, and 8,
primarily localizes in the nucleus where they regulate histone
acetylation. Class II of HDACs is divided into two subtypes:
c l a s sI I aa n dI I b .C l a s sI I ai n c l u d e sH D A C4 ,5 ,7 ,a n d9a n d
class IIb includes HDAC 6 and 10. Class IIa of HDACs shut-
tles between the nucleus and the cytoplasm in response to
certain cellular signals, whereas class IIb of HDACs mainly
locates in cytoplasm. In general, class III of HDAC is referred
to as “sirtuins.” Class III of HDACs includes SirT1-7, which
share homologous sequencewith the yeastSir2 protein; SIRT
3,4,and5aremitochondrialproteins[11].ClassIVHDACis
knowntohaveonlyonemember,HDAC11,whichcontainsa
catalytic domain located at the N-terminus. HDAC11 seems
to be closely related to HDAC3 and HDAC8 [12], and it also
mainly locates in the cellular nucleus [13].
2.2. Histone Deacetylase Inhibition and Alzheimer’s Disease.
In recent years, a variety of HDAC inhibitors have been de-
veloped (Table 1). The pan-HDAC inhibitors widely used in
clinical research are valproic acid, trichostatin A, sodium 4-
phenylbutyrate,andvorinostat;theseinhibitorsinteractwith
zinc-dependent HDAC protein (classI, classII,andclass IV).
Nicotinamide, as the precursor of NAD+, inhibits class III
HDAC proteins [14].
Valproic acid (VPA), as well as lithium, inhibits Aβ
peptide production in HEK293 cell transfected with Swedish
APP751 [15]. VPA also signiﬁcantly reduces Aβ plaque in AD
transgenic mice. VPA decreases Aβ production by inhibiting
GSK-3β-mediated γ-secretase cleavage of APP and alleviates
the memory deﬁcits in AD mouse model [16]. Ricobaraza
et al. suggested that 4-phenylbutyrate (PBA) decreases the
phosphorylation of tau based on an increase of an inactive
formoftheGSK-3βinTg2576mousemodelofAD[17].PBA
reinstates memory in both young and old Tg2576 mice and
reverses learning deﬁcits through clearance of intraneuronal
Aβ accumulation and mitigation of endoplasmic reticulum
(ER) stress [18]. Nicotinamide, a competitive inhibitor
of class III NAD+-dependent HDACs, restores cognitive
deﬁcits in 3xTg-AD mice. Nicotinamide selectively reduces
phosphorylation of tau at Thr231 site and increases the
acetylated α-tubulin [14]. Ding et al. found that tubacin-
treatedHEKcellstransfectedwithtausigniﬁcantlyattenuates
tau phosphorylation at T231 [19]. However, the untoward
eﬀects of pan-HDAC inhibitors limit their application to
clinic [20, 21]. Tubacin and suramin are the most studied
selective HDAC inhibitors; tubacin shows high selectivity for
HDAC6 [22], and suramin inhibits the activity of NAD+-
dependent class III SirT1 and SirT2 [23]. Here are the iso-
forms of HDACs, and the mainly used HDAC inhibitors are
listed in Table 1.
Above facts indicate that some HDAC proteins may have
a close relationship with those key proteins which are in-
volved in AD. HDAC inhibitors may be used to treat AD by
regulating the activity of HDAC proteins and phosphoryla-
tion of Tau. However, the mechanism of HDAC-regulated
cellular signaling in AD pathology is needed to further in-
vestigate.
3.Acetylationof Histoneand
Alzheimer’sDisease
Histone acetylation is involved in the gene expression
through chromatin modiﬁcation, and the acetylation was
mainly in the N-terminal of histone H3 and H4. The cog-
nitive deﬁcit is one of the major clinical characteristics of
AD patients. In mice, deregulation of histone acetylation is
associated with age-dependent memory impairment. Aged
mice display a speciﬁc deregulation of histone H4 lysine12
(H4K12) acetylation and fail to initiate a hippocampal gene
expression which is involved in memory consolidation, and
vorinostat-treatedmicedisplaysigniﬁcantincreaseofH4K12
acetylation and restore learning-induced gene expression
[24]. More and more evidence suggests that dysregulation of
histone H4 acetylation is involved in AD pathology. Kilgore
et al. reported that there is no diﬀerence in H3 or H4
acetylation in the hippocampus area between 6-month-old
APP/PS1 mice and wild-type mice, but a signiﬁcant re-
duction was observed in H4 acetylation in old APP/PS1
mice. The class I HDAC inhibitors sodium valproate,sodium
butyrate, or vorinostat elevate histone H4 acetylation and
restore contextual memory in a mouse model of AD [25].
Similarly, Francis et al. found that there is no diﬀerence in
the acetylation level of histone H4 between the 4-month-
old wild-type and the APP/PS1 mouse. After contextual fear-
conditioning training, the APP/PS1 mice display a reduced
endogenous level of histone H4 acetylation, and the mice
treated with trichostatin A (TSA), a class I and II HDAC
inhibitor, had improved acetylated histone H4 level and were
displayed hippocampal CA3-CA1 long-term potentiation
(LTP) [26]. Ricobaraza et al. reported that the acetylation of
histone H4 is decreased in the 16-month-old Tg2576 mouse
brain compared with nontransgenic controls, while there is
no diﬀerence in H3 acetylation. Phenylbutyrate, a class IIa
HDAC inhibitor, ameliorates the cognitive deﬁcits in Tg2576
mice and increases the neuronal acetylation of H4 and the
expression of synaptic plasticity markers including GluR1,
PSD95, and MAP2 [17]. What is more, in Tg2576 mouse
model of AD, the phenylbutyrate restores the dendritic spine
density of hippocampal CA1 pyramidal neurons and signiﬁ-
cantly increases the expression of plasticity-related proteins
like the NMDA receptor subunit NR2B and the synaptic
scaﬀold SAP102 [18]. Taken together, histone acetylation H4
isinvolvedinthepathologyofAD,andHDACinhibitorsmayOxidative Medicine and Cellular Longevity 3
Table 1: HDAC isoforms and main used of pan-HDAC inhibitors.
Histone subtype Protein Localization Main HDAC inhibitors
Class I (Zn++-dependent) HDAC1, 2, 3, and 8 Mainly nucleus Valproic acid, butyrate, vorinostat,
trichostatin A, RGFP136 (HDAC3)
Class IIa (Zn++-dependent) HDAC4, 5, 7, and 9 Nucleus/cytoplasm Trichostatin A, phenylbutyrate
Class IIb (Zn++-dependent) HDAC6 and 10 Mainly cytoplasm Tubacin (HDAC6), trichostatin A
ClassIII (NAD+-dependent) SirT1, 2, 3, 4, 5, 6, and 7 Nucleus/cytoplasm/Mitochondria Nicotinamide, suramin (SirT1 and SirT2),
Class IV (Zn++-dependent) HDAC11 Mainly nucleus
alter some important gene expression through regulating the
histone acetylation.
4. HistoneDeacetylasesand
Alzheimer’sDisease
HDACs inﬂuence the level of histone acetylation, and HDAC
inhibitors upregulate histone acetylation level and improve
memory and learning. The HDAC inhibitors aﬀect the acti-
vities of the proteins that play an important role in AD,
like Aβ,G S K - 3 β, and tau protein. GSK-3β, as a main tau
phosphokinase, is linked to several mechanisms involved in
AD. Increasing evidence suggests that Aβ induces hyper-
phosphorylation of tau though the activation of GSK-3β [27,
28]. Therefore, inhibition of Aβ-induced deﬁcits of histone
acetylation and hyperphosphorylation of tau is helpful to
treat AD. HDAC inhibitors downregulate HDAC activity and
thus increase the acetylation level of histone. At present,
however, most available HDAC inhibitors are nonselective
for HDACs because it is not fully understood which subtypes
o fH D A C sh a v ee ﬀects on development of AD. Identifying
whichsubtypesofHDACfamilymembersareinvolvedinthe
pathology of AD is needed to further investigate, speciﬁcally,
impairment of memory and learning.
4.1. Class I HDAC. Mice overexpressing HDAC2, but not
HDAC1, result in decreased synaptic plasticity, synapse
numberandmemoryformation,andvorinostatcouldrescue
the synaptic number and learning impairments in HDAC2-
overexpressing mice. Generally, HDAC2 negatively regulates
learning and memory [35]. Akhtar et al. demonstrated
that in mature neurons the upregulated level of HDAC2
aﬀects the basic excitatory neurotransmission, implying that
HDAC2 may play a role in synaptic plasticity [36].
McQuown et al. found that HDAC3-Flox-modiﬁed mice
(deletion of HDAC3 in the hippocampus of CA1 area) or the
mice treated with RGFP136 (selective inhibitor of HDAC3)
increase histone acetylation and signiﬁcantly enhance long-
term memory, and the expression of the genes of nuclear
receptor subfamily 4, group A, member 2 (Nr4a2) and c-
Fos is implicated in long-term memory [37]. Besides, Bar-
dai and d’Mello suggested that HDAC3 is a protein with
strong neurotoxic activity, and the toxic eﬀect is cellular
selective. HDAC3 is directly phosphorylated by GSK-3β,
and inhibition of GSK-3β protects against HDAC3-induced
neurotoxicity [38].
4.2. Class II HDAC. HDAC6, as a cytosolic enzyme, catalyzes
several nonhistone proteins, such as tubulin and HSP90 de-
acetylase [39, 40]. HDAC6 protein level in AD brains is
signiﬁcantly increased in cortex and hippocampus compared
with the normal brains. Tubacin (a selective inhibitor of
HDAC6) attenuates site-speciﬁc phosphorylation of tau,
suggesting that HDAC6 plays a role in the AD [19]. The
selective inhibition of HDAC6 dramatically enhances mito-
chondrial movement in hippocampal neurons. GSK-3β may
be involved in the active regulation of HDAC6 by phos-
phorylation pathway. Therefore, abnormal mitochondrial
transportation could be resulted from the misregulation of
HDAC6 by GSK-3β [41]. Besides, oxidative stress is the
main pathological feature of AD, and selective inhibition
of HDAC6 protects against oxidative-stress-induced neuro-
degeneration and promotes neurite outgrowth in cortical
neurons [42].
HDAC4 is mainly localized in the cytoplasm of brain
tissue,andabnormalexpressionofnuclear-localizedHDAC4
promotes neuronal apoptosis while inactivation of HDAC4
suppresses neuronal cell death [43]. Therefore, HDAC4 may
play an important role in nerve function.
4.3. Class III HDAC. Gao et al. found a signiﬁcant reduction
of SirT1 in the parietal cortex of AD patients compared with
the control, and the accumulation of Aβ and tau in the
AD patients may be associated with the loss of SirT1 [29].
Julien et al. suggested that the mutant mice with the lack of
SirT1 show impairment in memory and synaptic plasticity,
and SirT1 modulates synaptic plasticity and memory forma-
tion partly via the way of upregulation of miR-134 [30].
Therefore,SirT1couldbeatargetforthetreatmentofneuro-
degenerative disorders. Additionally, overexpression of the
NAD+-dependent deacetylase SirT1 in a mouse model of
AD reduces the production of Aβ and formation of plaques
through activating the transcription of gene encoding the α-
secretase ADAM10. SirT1 also regulates the Notch pathway,
which repairs neuronal damage in brains [31].
The level of α-tubulin acetylation is known to play an
important role in microtubule stability and SirT2 decreases
the level of α-tubulin deacetylation [14]. Taylor et al. sug-
gested that inhibition activity of SirT2 deacetylase reduces
total cholesterol in primary striatal neurons [32]. The above
facts hint that Sir2 is involved in the pathology of AD.
Kawamura et al. found out that RNAi-mediated SirT3
knockdown increases mitochondrial reactive oxygen species4 Oxidative Medicine and Cellular Longevity
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Figure 1: The role of HDAC inhibitors in Alzheimer’s disease. First, HDAC inhibitors inhibit Aβ-induced hyperphosphorylation of tau
protein. Second, HDAC inhibitors alter the expression of important genes which participate in the learning and memory.
(ROS) generation in mouse fertilized eggs, and the mito-
chondrial ROS generation is accompanied by the p53 up-
regulation in SirT3-knockdown mouse embryos [33]. Ad-
ditionally, the primary cultured mouse cortical neurons
treated with NMDA induce massive ROS production as well
as the increase of mitochondrial SirT3, while overexpression
of SirT3 signiﬁcantly reduces the mitochondrial ROS gener-
ation [34]. Therefore, the SirT3 appears to play a role in the
protection of the nervous system against excitotoxicity.
5. Summaries
AD is one of the most common forms of dementia. Current-
ly, the pathology of this disease is not fully understood.
“Amyloid cascade hypothesis” states that the increased Aβ
causes the disease progress, such as cognitive deﬁcits, mem-
ory impairment, and neuron loss. Accumulating evidence
supports the view that the HDAC proteins may be involved
in its development. The HDAC proteins may regulate the
level of histone acetylation and then alter the expression of
some important genes which are involved in the memory
and cognition and pathology of AD. HDAC inhibitors may
ameliorate cognitive deﬁcits and memory impairment in AD
animal models. The potential pathways of HDAC inhibitors
reversing Aβ-induced neurotoxicity may lie in that (1)
HDAC inhibitors inhibit Aβ-induced hyperphosphorylation
of tau protein; (2) HDAC inhibitors may regulate the ex-
pression of important genes that participate in the learning
and memory (Figure 1). However, many issues need to be
resolved before these inhibitors can be used to treat AD. For
example, it is not yet clear which subtypes of HDACs are
associated with the AD and which selective HDAC inhibitors
would be eﬀective to treat AD. Further researches are needed
to clarify the exact role of HDAC proteins and to develop
their selective inhibitors in the pathology of AD.
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